The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

Cancer Biol Med. 2017 Nov;14(4):341-347. doi: 10.20892/j.issn.2095-3941.2017.0090.

Authors

Amy L Cummings¹, Edward B Garon¹

Affiliation

¹ Department of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles 90095, USA.

PMID: 29372100
PMCID: PMC5785166
DOI: 10.20892/j.issn.2095-3941.2017.0090

No abstract available

Keywords: Immunotherapy; biomarkers; first-line treatment; immune checkpoint inhibitors.

Grants and funding

R01 CA208403/CA/NCI NIH HHS/United States